AAAAAA

   
Results: 1-22 |
Results: 22
Slowing down cerebral degeneration
Authors: Mattson, MP Greig, NH
Citation: Mp. Mattson et Nh. Greig, Slowing down cerebral degeneration, BIOFUTUR, 2001, 2001, pp. 51-53
Phenserine regulates translation of beta-amyloid precursor protein mRNA bya putative interleukin-1 responsive element, a target for drug development
Authors: Shaw, KTY Utsuki, T Rogers, J Yu, QS Sambamurti, K Brossi, A Ge, YW Lahiri, DK Greig, NH
Citation: Kty. Shaw et al., Phenserine regulates translation of beta-amyloid precursor protein mRNA bya putative interleukin-1 responsive element, a target for drug development, P NAS US, 98(13), 2001, pp. 7605-7610
A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide
Authors: Culmsee, C Zhu, XX Yu, QS Chan, SL Camandola, S Guo, ZH Greig, NH Mattson, MP
Citation: C. Culmsee et al., A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide, J NEUROCHEM, 77(1), 2001, pp. 220-228
Methyl analogues of the experimental Alzheimer drug phenserine: Synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action
Authors: Yu, QS Holloway, HW Flippen-Anderson, JL Hoffman, B Brossi, A Greig, NH
Citation: Qs. Yu et al., Methyl analogues of the experimental Alzheimer drug phenserine: Synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action, J MED CHEM, 44(24), 2001, pp. 4062-4071
Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent
Authors: Doyle, ME Greig, NH Holloway, HW Betkey, JA Bernier, M Egan, JM
Citation: Me. Doyle et al., Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent, ENDOCRINOL, 142(10), 2001, pp. 4462-4468
(-)-(3aS)-eseroline carbamate (II), a potent cholinesterase inhibitor and close analogue of physostigmine: Reanalysis
Authors: Yu, QS Greig, NH Holloway, HW Flippen-Anderson, JL Brossi, A
Citation: Qs. Yu et al., (-)-(3aS)-eseroline carbamate (II), a potent cholinesterase inhibitor and close analogue of physostigmine: Reanalysis, MED CHEM RE, 10(3), 2000, pp. 186-199
Time course of pharmacodynamic and pharmacokinetic effects of physostigmine assessed by functional brain imaging in humans
Authors: Furey, ML Pietrini, P Alexander, GE Mentis, MJ Szczepanik, J Shetty, U Greig, NH Holloway, HW Schapiro, MB Freo, U
Citation: Ml. Furey et al., Time course of pharmacodynamic and pharmacokinetic effects of physostigmine assessed by functional brain imaging in humans, PHARM BIO B, 66(3), 2000, pp. 475-481
Butyrylcholinesterase accelerates cocaine metabolism: In vitro and in vivoeffects in nonhuman primates and humans
Authors: Carmona, GN Jufer, RA Goldberg, SR Gorelick, DA Greig, NH Yu, QS Cone, EJ Schindler, CW
Citation: Gn. Carmona et al., Butyrylcholinesterase accelerates cocaine metabolism: In vitro and in vivoeffects in nonhuman primates and humans, DRUG META D, 28(3), 2000, pp. 367-371
A practical conversion of natural physostigmine into the potent butyrylcholinesterase inhibitor N-1,N-8-bisnorcymserine
Authors: Zhu, XX Greig, NH Holloway, HW Whittaker, NF Brossi, A Yu, QS
Citation: Xx. Zhu et al., A practical conversion of natural physostigmine into the potent butyrylcholinesterase inhibitor N-1,N-8-bisnorcymserine, TETRAHEDR L, 41(25), 2000, pp. 4861-4864
Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats
Authors: Szayna, M Doyle, ME Betkey, JA Holloway, HW Spencer, RGS Greig, NH Egan, JM
Citation: M. Szayna et al., Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats, ENDOCRINOL, 141(6), 2000, pp. 1936-1941
Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine
Authors: Kamal, MA Greig, NH Alhomida, AS Al-Jafari, AA
Citation: Ma. Kamal et al., Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine, BIOCH PHARM, 60(4), 2000, pp. 561-570
Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease
Authors: Lahiri, DK Farlow, MR Hintz, N Utsuki, T Greig, NH
Citation: Dk. Lahiri et al., Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease, ACT NEUR SC, 102, 2000, pp. 60-67
The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics
Authors: Greig, NH De Micheli, E Holloway, HW Yu, QS Utsuki, T Perry, TA Brossi, A Ingram, DK Deutsch, J Lahiri, DK Soncrant, TT
Citation: Nh. Greig et al., The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics, ACT NEUR SC, 102, 2000, pp. 74-84
Syntheses and biological evaluation of ring-C opened analogues of the cholinesterase inhibitors physostigmine, phenserine and cymserine
Authors: Pei, XF Yu, QS Holloway, HW Brossi, A Greig, NH
Citation: Xf. Pei et al., Syntheses and biological evaluation of ring-C opened analogues of the cholinesterase inhibitors physostigmine, phenserine and cymserine, MED CHEM RE, 9(1), 1999, pp. 50-60
Chemokine receptor mRNA expression at the in vitro blood-brain barrier during HIV infection (vol 10, pg 53, 1999)
Authors: Shaw, KTY Greig, NH
Citation: Kty. Shaw et Nh. Greig, Chemokine receptor mRNA expression at the in vitro blood-brain barrier during HIV infection (vol 10, pg 53, 1999), NEUROREPORT, 10(4), 1999, pp. COVER3-COVER3
Chemokine receptor mRNA expression at the in vitro blood-brain barrier during HIV infection
Authors: Shaw, KTY Greig, NH
Citation: Kty. Shaw et Nh. Greig, Chemokine receptor mRNA expression at the in vitro blood-brain barrier during HIV infection, NEUROREPORT, 10(1), 1999, pp. 53-56
Neuroendocrine responses to intravenous infusion of physostigmine in patients with Alzheimer disease
Authors: Asthana, S Raffaele, KC Greig, NH Schapiro, MB Blackman, MR Soncrant, TT
Citation: S. Asthana et al., Neuroendocrine responses to intravenous infusion of physostigmine in patients with Alzheimer disease, ALZ DIS A D, 13(2), 1999, pp. 102-108
4 '-hydroxyphenylcarbamates of (3aS)-eseroline and (3aS)-N(1)-noreseroline: Potential metabolites of the Alzheimer's anticholinesterase drug phenserine
Authors: Yu, QS Greig, NH Holloway, HW Brossi, A
Citation: Qs. Yu et al., 4 '-hydroxyphenylcarbamates of (3aS)-eseroline and (3aS)-N(1)-noreseroline: Potential metabolites of the Alzheimer's anticholinesterase drug phenserine, HETEROCYCLE, 50(1), 1999, pp. 95-102
Cerebrovascular biology and the various neural barriers: Challenges and future directions
Authors: Neuwelt, EA Abbott, NJ Drewes, L Smith, QR Couraud, PO Chiocca, EA Audus, KL Greig, NH Doolittle, ND
Citation: Ea. Neuwelt et al., Cerebrovascular biology and the various neural barriers: Challenges and future directions, NEUROSURGER, 44(3), 1999, pp. 604-608
Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease
Authors: Yu, QS Holloway, HW Utsuki, T Brossi, A Greig, NH
Citation: Qs. Yu et al., Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease, J MED CHEM, 42(10), 1999, pp. 1855-1861
Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations
Authors: Greig, NH Holloway, HW De Ore, KA Jani, D Wang, Y Zhou, J Garant, MJ Egan, JM
Citation: Nh. Greig et al., Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations, DIABETOLOG, 42(1), 1999, pp. 45-50
Syntheses and biological evaluation of (+/-)-3a-phenyl congeners of physostigmine and phenserine
Authors: Pei, XF Greig, NH Brossi, A
Citation: Xf. Pei et al., Syntheses and biological evaluation of (+/-)-3a-phenyl congeners of physostigmine and phenserine, HETEROCYCLE, 49, 1998, pp. 437-444
Risultati: 1-22 |